Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 3/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20063342 | 1.00 | PKM (0.38) | PKMMEN1KMT2ASMN1; SMN2HSD17B10 | |
| SCHEMBL22152385 | 0.90 | BCHE (0.41) | MEN1KMT2ASMN1; SMN2BCHEALDH1A1 | |
| SCHEMBL18389965 | 0.89 | MEN1 (0.38) | MEN1KMT2ASMN1; SMN2HSD17B10GAA | |
| SCHEMBL23296572 | 0.82 | PKM (0.37) | PKMMEN1KMT2ASMN1; SMN2HSD17B10 | |
| SCHEMBL23296574 | 0.82 | PKM (0.37) | PKMMEN1KMT2ASMN1; SMN2HSD17B10 | |
| SCHEMBL29542824 | 0.81 | PKM (0.34) | PKMMEN1KMT2ASMN1; SMN2HSD17B10 | |
| SCHEMBL14155735 | 0.81 | BCHE (0.47) | PKMMEN1KMT2ASMN1; SMN2HSD17B10 | |
| SCHEMBL12225732 | 0.81 | BCHE (0.47) | PKMMEN1KMT2ASMN1; SMN2HSD17B10 | |
| SCHEMBL2743218 | 0.81 | BCHE (0.47) | PKMMEN1KMT2ASMN1; SMN2HSD17B10 | |
| SCHEMBL22152623 | 0.81 | HRH3 (0.38) | MEN1KMT2ASMN1; SMN2HSD17B10GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200115354-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2020-04-16 | — | — | US | disclosed |
| US-20180105504-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200115354-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | NPY5R, REN, F12 | PKM 2488/4885MEN1 130/4885KMT2A 3719/4885 |
| US-20180105504-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | NPY5R, REN, F12 | PKM 2407/4885MEN1 139/4885KMT2A 3753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.